123 related articles for article (PubMed ID: 26746214)
1. Targeting BRAF mutants in clear-cell sarcomas of soft tissue: beyond sarcoma or melanoma classification.
Uguen A; Marcorelles P; De Braekeleer M
Invest New Drugs; 2016 Apr; 34(2):253-4. PubMed ID: 26746214
[No Abstract] [Full Text] [Related]
2. BRAF-mutated clear cell sarcoma is sensitive to vemurafenib treatment.
Protsenko SA; Semionova AI; Komarov YI; Aleksakhina SN; Ivantsov AO; Iyevleva AG; Imyanitov EN
Invest New Drugs; 2015 Oct; 33(5):1136-43. PubMed ID: 26286452
[TBL] [Abstract][Full Text] [Related]
3. Concerns regarding BRAF testing algorithm.
Clark RR; Garioch JJ; Moncrieff MD
Br J Dermatol; 2013 Nov; 169(5):1167-8. PubMed ID: 23855527
[No Abstract] [Full Text] [Related]
4. Community experience of vemurafenib for BRAF(V600) melanoma.
Hersey P
Lancet Oncol; 2014 Apr; 15(4):369-70. PubMed ID: 24582506
[No Abstract] [Full Text] [Related]
5. Concerns regarding BRAF testing algorithm: reply from authors.
Gonzalez D; Fearfield L; Nathan P; Tanière P; Wallace A; Brown E; Harwood C; Marsden J; Whittaker S
Br J Dermatol; 2013 Nov; 169(5):1168-70. PubMed ID: 23855556
[No Abstract] [Full Text] [Related]
6. BRAF(V600) mutation levels predict response to vemurafenib in metastatic melanoma.
Lebbé C; How-Kit A; Battistella M; Sadoux A; Podgorniak MP; Sidina I; Pages C; Roux J; Porcher R; Tost J; Mourah S
Melanoma Res; 2014 Aug; 24(4):415-8. PubMed ID: 24933605
[No Abstract] [Full Text] [Related]
7. Rapidly metastasizing malignant melanoma characterized by a rare BRAF mutation not responding to vemurafenib.
Starz H; Gutschi M; Welzel J; Haas C
J Dtsch Dermatol Ges; 2014 Feb; 12(2):151-4. PubMed ID: 24238398
[No Abstract] [Full Text] [Related]
8. Spindle cell squamous cell carcinoma arising from verrucous hyperplasia during BRAF inhibitor therapy for melanoma.
Ziemer M; Pönitzsch I; Simon JC; Schüürmann M
J Dtsch Dermatol Ges; 2015 Apr; 13(4):326-8. PubMed ID: 25761417
[No Abstract] [Full Text] [Related]
9. Vemurafenib therapy for stage IV melanoma with V600G-mutation.
Lang N; Weisser A; Enk A; Hassel JC
J Dtsch Dermatol Ges; 2013 Dec; 11(12):1198-9. PubMed ID: 24016000
[No Abstract] [Full Text] [Related]
10. Successful treatment with vemurafenib in BRAF V600K-positive cerebral melanoma metastasis.
Forschner A; Niessner H; Bauer J; Bender B; Garbe C; Meier F
JAMA Dermatol; 2013 May; 149(5):642-4. PubMed ID: 23677116
[No Abstract] [Full Text] [Related]
11. Clinical Pharmacokinetics of Vemurafenib in BRAF-Mutated Melanoma Patients.
Nijenhuis CM; Huitema AD; Blank C; Haanen JB; van Thienen JV; Rosing H; Schellens JH; Beijnen JH
J Clin Pharmacol; 2017 Jan; 57(1):125-128. PubMed ID: 27365214
[No Abstract] [Full Text] [Related]
12. New drug for metastatic melanoma increases survival rate.
Carter D
Am J Nurs; 2011 Sep; 111(9):16. PubMed ID: 21865918
[No Abstract] [Full Text] [Related]
13. Vemurafenib: a guide to its use in unresectable or metastatic melanoma.
Keating GM; Lyseng-Williamson KA
Am J Clin Dermatol; 2013 Feb; 14(1):65-9. PubMed ID: 23329082
[TBL] [Abstract][Full Text] [Related]
14. Absent response of intracranial melanoma metastases harboring BRAF V600E sequence variation to vemurafenib.
D'Alonzo D; Glatz K
Mayo Clin Proc; 2013 Dec; 88(12):e151-2. PubMed ID: 24290130
[No Abstract] [Full Text] [Related]
15. Cutaneous manifestations of vemurafenib therapy for metastatic melanoma.
Owen JL; Lopez IE; Desai SR
J Drugs Dermatol; 2015 May; 14(5):509-10. PubMed ID: 25942671
[TBL] [Abstract][Full Text] [Related]
16. Vemurafenib as neoadjuvant treatment for unresectable regional metastatic melanoma.
Koers K; Francken AB; Haanen JB; Woerdeman LA; van der Hage JA
J Clin Oncol; 2013 Jun; 31(16):e251-3. PubMed ID: 23569313
[No Abstract] [Full Text] [Related]
17. Colorectal cancer: Targeting BRAF mutations equally?
Hutchinson L
Nat Rev Clin Oncol; 2016 Jan; 13(1):4. PubMed ID: 26552951
[No Abstract] [Full Text] [Related]
18. Second primary melanoma on a patient undergoing vemurafenib therapy. A case report.
Onnis G; Palmieri G; Montesu MA; Satta R
Int J Dermatol; 2017 Jul; 56(7):792-794. PubMed ID: 28345133
[TBL] [Abstract][Full Text] [Related]
19. Strides in melanoma announced: maximizing value comes next.
Tuma RS
J Natl Cancer Inst; 2011 Jul; 103(13):997-9. PubMed ID: 21693727
[No Abstract] [Full Text] [Related]
20. Overcoming metastatic melanoma with BRAF inhibitors.
Hong S; Hong S; Han SB
Arch Pharm Res; 2011 May; 34(5):699-701. PubMed ID: 21656352
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]